Covis' controversial Makena gets FDA hearing date in bid to stay on the market

More than a decade after Makena's FDA approval to prevent recurrent preterm birth and two years after the FDA recommended the drug be pulled from the market, Covis Pharma has locked down a hearing date to fight for the med's future.